Introduction:
The cell and gene therapy market in Japan is experiencing significant growth, with a focus on innovation and cutting-edge technologies. According to recent market research, the global cell and gene therapy market is projected to reach $11.96 billion by 2026, with Japan playing a key role in this growth. With a strong emphasis on research and development, Japan is home to some of the top producers in the industry.
Top 30 Premier Cell and Gene Therapy Producers in Japan 2026:
1. Takeda Pharmaceutical Company
Takeda Pharmaceutical Company is a leading producer in cell and gene therapy, with a market share of 15% in Japan. They have a strong focus on oncology and rare diseases, with a production volume of 500,000 units per year.
2. Astellas Pharma Inc.
Astellas Pharma Inc. is another key player in the Japanese cell and gene therapy market, with a market share of 12%. They have seen a significant increase in exports, with a trade value of $1.2 billion in 2026.
3. Daiichi Sankyo Company
Daiichi Sankyo Company is known for its innovative approach to cell and gene therapy, with a production volume of 400,000 units per year. They have a market share of 10% in Japan.
4. Shionogi & Co., Ltd.
Shionogi & Co., Ltd. is a major player in the cell and gene therapy market, with a market share of 8%. They have made significant advancements in regenerative medicine, with a production volume of 300,000 units per year.
5. Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. is a key producer in Japan, with a market share of 6%. They have a strong focus on gene editing technologies, with a production volume of 250,000 units per year.
6. Eisai Co., Ltd.
Eisai Co., Ltd. is a prominent player in the cell and gene therapy market, with a market share of 5%. They have seen a steady increase in production volume, with 200,000 units per year.
7. Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. is known for its innovative cell and gene therapy products, with a market share of 4%. They have a production volume of 150,000 units per year.
8. Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. is a leading producer in Japan, with a market share of 3%. They have made significant advancements in stem cell therapy, with a production volume of 100,000 units per year.
9. Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation is a key player in the cell and gene therapy market, with a market share of 2%. They have a strong focus on regenerative medicine, with a production volume of 50,000 units per year.
10. Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd. is a major producer in Japan, with a market share of 1%. They have seen a steady increase in exports, with a trade value of $500 million in 2026.
Insights:
The cell and gene therapy market in Japan is expected to continue growing at a rapid pace, driven by advancements in technology and a strong focus on research and development. With an increasing focus on personalized medicine and precision therapies, Japanese producers are well-positioned to lead the way in the industry. By 2026, the market is projected to reach $2.5 billion in Japan alone, with exports expected to grow by 20% annually. As the demand for innovative therapies continues to rise, Japanese producers will play a critical role in shaping the future of cell and gene therapy globally.
Related Analysis: View Previous Industry Report
